Integra LifeSciences (IART) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Integra LifeSciences (NASDAQ: IART):

• 10/5/2026 – Integra LifeSciences had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $15.00 price target on the stock, down from $19.00.
• 10/5/2026 – Integra LifeSciences had its price target lowered by BMO Capital Markets from $18.00 to $15.00. They now have a “market perform” rating on the stock.
• 10/3/2026 – Integra LifeSciences was given a new $15.00 price target by Wells Fargo & Company.
• 10/3/2026 – Integra LifeSciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/2/2026 – Integra LifeSciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/1/2026 – Integra LifeSciences was upgraded by Truist Financial Corporation to “hold”.
• 8/14/2026 – Integra LifeSciences was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.